Pfizer's Covid-19 vaccine was 90.7% effective in 5 to 11 year olds in clinical trials, according to new FDA documents. CNBC's Meg Tirrell reports. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
Kid-size doses of Pfizer’s Covid-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.